Long Quan-Xin, Jia Yan-Jun, Wang Xin, Deng Hai-Jun, Cao Xiao-Xia, Yuan Jun, Fang Liang, Cheng Xu-Rong, Luo Chao, He An-Ran, Tang Xiao-Jun, Hu Jie-Li, Hu Yuan, Tang Ni, Cai Xue-Fei, Wang De-Qiang, Hu Jie, Qiu Jing-Fu, Liu Bei-Zhong, Chen Juan, Huang Ai-Long
Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, 400016, China.
Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Cell Discov. 2021 Mar 25;7(1):18. doi: 10.1038/s41421-021-00250-9.
It is important to evaluate the durability of the protective immune response elicited by primary infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we systematically evaluated the SARS-CoV-2-specific memory B cell and T cell responses in healthy controls and individuals recovered from asymptomatic or symptomatic infection approximately 6 months prior. Comparatively low frequencies of memory B cells specific for the receptor-binding domain (RBD) of spike glycoprotein (S) persisted in the peripheral blood of individuals who recovered from infection (median 0.62%, interquartile range 0.48-0.69). The SARS-CoV-2 RBD-specific memory B cell response was detected in 2 of 13 individuals who recovered from asymptomatic infection and 10 of 20 individuals who recovered from symptomatic infection. T cell responses induced by S, membrane (M), and nucleocapsid (N) peptide libraries from SARS-CoV-2 were observed in individuals recovered from coronavirus disease 2019 (COVID-19), and cross-reactive T cell responses to SARS-CoV-2 were also detected in healthy controls.
评估由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）初次感染引发的保护性免疫反应的持久性很重要。在此，我们系统地评估了健康对照者以及约6个月前从无症状或有症状感染中康复的个体中SARS-CoV-2特异性记忆B细胞和T细胞反应。从感染中康复的个体外周血中，针对刺突糖蛋白（S）受体结合域（RBD）的记忆B细胞频率相对较低（中位数0.62%，四分位间距0.48 - 0.69）。在13名从无症状感染中康复的个体中有2名以及20名从有症状感染中康复的个体中有10名检测到了SARS-CoV-2 RBD特异性记忆B细胞反应。在从2019冠状病毒病（COVID-19）中康复的个体中观察到了由SARS-CoV-2的刺突蛋白（S）、膜蛋白（M）和核衣壳蛋白（N）肽库诱导的T细胞反应，并且在健康对照者中也检测到了对SARS-CoV-2的交叉反应性T细胞反应。
